Hossein-Ardeschir Ghofrani
Overview
Explore the profile of Hossein-Ardeschir Ghofrani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
113
Citations
5546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Eichstaedt C, Sassmannshausen Z, Shaukat M, Cao D, Xanthouli P, Gall H, et al.
Respir Res
. 2022 Mar;
23(1):74.
PMID: 35346192
Background: A genetic predisposition can lead to the rare disease pulmonary arterial hypertension (PAH). Most mutations have been identified in the gene BMPR2 in heritable PAH. However, as of today...
22.
Benza R, Farber H, Frost A, Ghofrani H, Corris P, Lambelet M, et al.
Respir Med
. 2022 Mar;
195:106783.
PMID: 35256218
Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for...
23.
Benza R, Boucly A, Farber H, Frost A, Ghofrani H, Hoeper M, et al.
J Heart Lung Transplant
. 2021 Dec;
41(3):411-420.
PMID: 34848133
Background: Risk assessment is essential in pulmonary arterial hypertension (PAH) management. We investigated the effect of riociguat on REVEAL Lite 2 score, an abridged version of the REVEAL risk score,...
24.
Rosenkranz S, Channick R, Chin K, Jenner B, Gaine S, Galie N, et al.
Eur J Heart Fail
. 2021 Nov;
24(1):205-214.
PMID: 34806261
Aims: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses...
25.
Frantz R, Benza R, Channick R, Chin K, Howard L, McLaughlin V, et al.
Pulm Circ
. 2021 Nov;
11(4):20458940211057071.
PMID: 34790348
Aberrant kinase signaling that involves platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c-KIT) pathways may be responsible for vascular remodeling...
26.
Benza R, Ghofrani H, Grunig E, Hoeper M, Jansa P, Jing Z, et al.
J Heart Lung Transplant
. 2021 Aug;
40(10):1172-1180.
PMID: 34353714
Background: In the Phase III PATENT-1 (NCT00810693) and CHEST-1 (NCT00855465) studies, riociguat demonstrated efficacy vs placebo in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Clinical...
27.
Sommer N, Weissmann N, Ghofrani H
Circulation
. 2021 Jun;
143(23):2273-2276.
PMID: 34097444
No abstract available.
28.
Benza R, Farber H, Frost A, Ghofrani H, Corris P, Lambelet M, et al.
Int J Cardiol
. 2021 Mar;
332:189-192.
PMID: 33744348
Background: Regular risk assessment is recommended in pulmonary arterial hypertension (PAH) management to improve patient outcomes. The REVEAL risk score (RRS) predicts survival in patients with PAH, including those from...
29.
Valerio L, Barco S, Jankowski M, Rosenkranz S, Lankeit M, Held M, et al.
Chest
. 2021 Feb;
159(6):2428-2438.
PMID: 33548221
Background: Few data are available on the long-term course and predictors of quality of life (QoL) following acute pulmonary embolism (PE). Research Question: What are the kinetics and determinants of...
30.
Gaine S, Sitbon O, Channick R, Chin K, Sauter R, Galie N, et al.
Chest
. 2021 Feb;
160(1):277-286.
PMID: 33545163
Background: Early initiation of pulmonary arterial hypertension (PAH) therapies is associated with improved long-term outcomes, yet data on the early use of prostacyclin pathway agents are limited. In these post...